ClinicalTrials.gg
RecruitingNCT07301177PTP-NPUpdated Dec 24, 2025

DoD AtMS for Posttraumatic Peripheral Neuropathic Pain

An interventional study of Transcutaneous magnetic stimulation (tMS) and Sham transcutaneous magnetic stimulation (Sham-tMS) in Posttraumatic Peripheral Neuropathic Pain, Peripheral Neuropathy and Peripheral Neuropathy Due to Surgical Trauma, sponsored by Veterans Medical Research Foundation. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Veterans Medical Research Foundation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies in Peripheral Nervous System Diseases with a site in United States — 31 open to participants now, 48 under way, 2 of them phase 3. Peripheral Nervous System Diseases · United States.

Planned enrollment
24th of 157
180 · median 43
Started
2025
with 6 others
No phase
91 of 191
19 open now
Primary completion
2028-11
later than 39 of 46 live
Registered
180th of 191
by date

Among the 191 studies in Peripheral Nervous System Diseases with a site in United States, this one is the 24th largest by planned enrollment of the 157 interventional ones that give a count, is one of 7 that started in 2025, is one of 91 with no phase, reaches primary completion later than 39 of the 46 other live ones, and was the 180th registered.

Peripheral Nervous System Diseases

476 studies on the registry are indexed under Peripheral Nervous System Diseases; 103 are open to participants now.

Browse Peripheral Nervous System Diseases studies →

Open to participants now

31 of the 191 studies in Peripheral Nervous System Diseases with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Peripheral Nervous System Diseases studies recruiting now, 44 (68%) set no upper age limit and 10 (15%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Peripheral Nervous System Diseases with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if adaptative transcutaneous magnetic stimulation (AtMS) works to reduce pain caused by post-traumatic peripheral neuropathic pain (PTP-NP) within Veterans and/or active duty military personnel. It will also learn about the safety of AtMS. The main questions it aims to answer are:

  1. What are the effects of adaptative tMS (AtMS) in alleviating patients' PTP-NP compared to fixed tMS (FtMS) and Sham-tMS?
  2. What are the effects of AtMS in improving functions in patients suffering from PTP-NP compared to FtMS and Sham-tMS?
  3. What are the effects of AtMS in improving mood in patients suffering from PTP NP compared FtMS and Sham-tMS?

Researchers will compare AtMS, FtMS and Sham-tMS to see if AtMS is the best form of tMS in treating PTP-NP.

Participants will undergo the following:

  1. Receive a total of 8 AtMS, FtMS, or Sham-tMS treatments over 16 weeks.
  2. Visit the clinic a total of 12 times for assessments, check ups, and treatments.
  3. Keep a daily diary of their PTP-NP intensity, sleep interference, and pain medications used.
Read the detailed description

This study will be enrolling a total of 144 veterans or active military over a 4 year period at the VA San Diego Healthcare System (VASDHS). Participants will be randomized into one of three groups:

Group A: AtMS Group B: FtMS Group C: Sham-tMS

Individual participation will consist of 12 visits to the VASDHS over the course of 5 months. The visits will be divided into the following phases:

  1. PRE-TREATMENT ASSESSMENTS PHASE (weeks 1-2) which consists of Visit 1 (Screening Visit) and Visit 2 (Baseline Assessments)
  2. INDUCTION TREATMENT PHASE (weeks 3-4) consists of Visits 3-7 (5 weekday tMS sessions at >24 and \<72 hours apart); and
  3. POST-TREATMENT ASSESSMENTS AND MAINTENANCE TREATMENT PHASE (weeks 6-20) consists of 2 initial biweekly post-induction treatment assessments and maintenance treatments (Visits 8 and 9), and two additional monthly post-induction treatment assessments and maintenance treatments (Visits 10 and 11) and one final study visit (Visit 12)
03

Conditions studied

  • Posttraumatic Peripheral Neuropathic Pain
  • Peripheral Neuropathy
  • Peripheral Neuropathy Due to Surgical Trauma
  • Peripheral Neuropathy Due to Physical Trauma

Keywords

  • adaptative transcutaneous magnetic stimulation (AtMS)
  • fixed transcutaneous magnetic stimulation (ftMS)
  • transcutaneous magnetic stimulation (tMS)
  • peripheral neuropathy
  • neuropathy
  • pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Veterans (men or women) of any race or ethnicity who are at least 18 years of age
  • Chronic peripheral neuropathic pain present for more than 4 months after a traumatic or surgical event per medical history
  • Have an average daily Numerical Pain Rating Scale (NPRS) score > 3
  • At least one negative or positive sensory sign or symptom confined to innervation territory of the lesioned nervous structure
  • Prior diagnostic tests confirming lesion or disease explaining neuropathic

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Subjects with central neuropathic pain (ex: due to diabetic peripheral neuropathy, , chemo/anti-viral therapy, carpal tunnel syndrome, post-traumatic pain classified as central rather than peripheral)
  • Subjects with pain due to Complex Regional Pain Syndrome
  • Phantom limb pain after amputation (stump pain and phantom sensation are allowed)
  • Subjects with skin conditions in the affected dermatome
  • Subjects with other pain such as lumbar or cervical radiculopathy that may confound assessment
  • Any subject considered at risk of suicide
  • Use of prohibited medications in the absence of appropriate
  • Participation in any other clinical trial within the 30 days prior to screening and/or during participation in this study
  • Heart pacemaker
  • Subjects with a current diagnosis of Axis I disorder (GAD \& MDD are allowed if clinically stable)
  • Subjects with pending lawsuits related to injury
  • Subjects who have previously received either transcranial or transcutaneous magnetic stimulation therapy in the past
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    Adaptive transcutaneous magnetic stimulation (AtMS)

    The adaptive transcutaneous magnetic stimulation (AtMS) arm uses a patient machine interface (PMI) to determine what intensity to set the study tMS treatments. Treatment is then performed with an active tMS coil.

    Device: Transcutaneous magnetic stimulation (tMS) · Device: Patient Machine Interface (PMI)

  • Active comparator
    Fixed transcutaneous magnetic stimulation (FtMS)

    The fixed transcutaneous magnetic stimulation (FtMS) arm uses a patient machine interface (PMI) to determine an intensity which is then multiplied by 1.5 during the first treatment session. This calculated intensity is used for every treatment session going forward, although the subject will still engage with the PMI every session. Treatments are performed using an active tMS coil.

    Device: Transcutaneous magnetic stimulation (tMS) · Device: Patient Machine Interface (PMI)

  • Sham comparator
    Sham transcutaneous magnetic stimulation (Sham-tMS)

    The sham transcutaneous magnetic stimulation (Sham-tMS) arm uses the patient machine interface (PMI) to determine the intensity to set the study tMS treatments for each visit. Treatment is performed using a sham tMS coil that sounds and feels the same.

    Device: Sham transcutaneous magnetic stimulation (Sham-tMS) · Device: Patient Machine Interface (PMI)

Interventions

  • DeviceTranscutaneous magnetic stimulation (tMS)

    Active tMS will be given at different PTP-NP sites with an active tMS coil.

  • DeviceSham transcutaneous magnetic stimulation (Sham-tMS)

    Sham-tMS will be given at different PTP-NP sites with a sham tMS coil. All parameters of the treatment will appear identical to the active treatment.

  • DevicePatient Machine Interface (PMI)

    The PMI will be used to help determine intensities for tMS treatments.

06

What researchers measure

Primary outcomes

  1. Neuropathic Pain Rating

    0 is equivalent to no neuropathic pain and 10 indicates the worst possible neuropathic pain

    Time frame: From enrollment to the end of treatment at 20 weeks

  2. Mood

    Hamilton Rating Scale for Depression (HRSD) an interviewed asks 21 questions about mood, sleep, appetite, and other symptoms related to depression. The interviewer rates the severity of each symptom based on a pre-defined scale of 0-4. The scores for each item are then summed to produce a total score. The total score on the HAM-D is used to assess the severity of depression. Lower scores indicate less severe depression, while higher scores indicate more severe depression. Typical scoring interpretations: Below 7: Absence or remission of depression; 7-17: Mild depression; 18-24: Moderate depression; 25 and above: Severe depression

    Time frame: From baseline to the end of treatment at 20 weeks

  3. Quality of Life (Sleep Interference)

    Daily Sleep Interference Log measures how much neuropathic pain impacts the patients sleep each night. The log is ranked on a 0 to 10 scale, 0 being pain didn't interfere with sleep and 10 being pain completely interfered with sleep, with a lower score representing a better outcome.

    Time frame: From enrollment to the end of treatment at 20 weeks

  4. Functionality - Absenteeism

    Work Productivity and Activity Impairment Questionnaire (WPAI-SHP version 2) metric 1: Absenteeism (the percentage of work time missed); \*\*\*Only those being employed provided answer for absenteeism\*\*\* WPAI absenteeism scores are based 2-items (2 and 4); a score cannot be calculated if there is a missing response to the corresponding item. Question 2 represents time in hours lost due to health reasons while question 4 represents the time spent working. Time lost is divided by the total time (sum of 2 and 4) and then multiplied by 100 to express as a percentage. All WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity

    Time frame: From baseline to the end of treatment at 20 weeks

  5. Functionality - Presenteeism

    Work Productivity and Activity Impairment Questionnaire (WPAI-SHP version 2) metric 2: Presenteeism (the percentage of impairment experienced while at work); \*\*\*Only those being employed provided answer for presenteeism\*\*\* WPAI presenteeism scores are based on 1-item (5) which is divided by 10 and later multiplied by 100 to express as a percentage; a score cannot be calculated if there is a missing response to the corresponding item. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity

    Time frame: From baseline to the end of treatment at 20 weeks

  6. Functionality - Overall work Productivity Impairment

    Work Productivity and Activity Impairment Questionnaire (WPAI-SHP version 2) metric 3: Overall work productivity loss (an estimate of combination of absenteeism and presenteeism); \*\*\*Only those being employed provided answer for absenteeism {Q2/(Q2+Q4)}, presenteeism {Q5/10}\*\*\* WPAI overall work productivity scores are computed based on absenteeism and presenteeism scores, using the following formula, Q2/(Q2+Q4)+\[(1-(Q2/(Q2+Q4)))x(Q5/10)\], and then being multiplied by 100 to express as a percentage; a score cannot be calculated if there is a missing response to the corresponding item. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity

    Time frame: From baseline to the end of treatment at 20 weeks

  7. Functionality - Activity Impairment

    Work Productivity and Activity Impairment Questionnaire (WPAI-SHP version 2) metric 4: Activity impairment (the percentage of impairment in daily activities) \*\*\*Only those being employed provided answer for absenteeism, presenteeism, and overall work impairment\*\*\* WPAI activity impairment scores are based on 1-item (item 6) which is divided by 10 and later multiplied by 100 to express as a percentage; a score cannot be calculated if there is a missing response to the corresponding item. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity

    Time frame: From baseline to the end of treatment at 20 weeks

Secondary outcomes

  1. Neuropathic Pain Medication Usage

    Neuropathic Pain Medication Logs will measure changes in daily neuropathic pain. The log will record if daily neuropathic pain medications are used, the medication name(s), the strength(s) measured in mg, quantity measured by number of pills/sprays/etc. As well as if additional non-daily, typically OTC, pain medications were taken for neuropathy, the medication name(s), strength(s) measured in mg, quantity measured by number of pills/spray/etc. For this outcome, increases in any medication as well as new medications will be marked as "more" and numerically described with 1; decreases will be marked as "less" and numerically described as -1; no change will result in a 0. Total change will be summed per visit and later used as a percentage of participants positive (representing an increase in medication us) or negative (decrease in medication use) change. Any negative score will be considered a favorable outcome.

    Time frame: From enrollment to the end of treatment at 20 weeks

  2. Allodynia Area Mapping (Von Frey)

    von Frey 5.18 monofilament will be used to measure/map (cm²) out an area of neuropathic allodynia. The instrument will be used by pressing them against the neuropathic pain area and marking roughly 8 points with each. Then the points will be traced on two separate translucent papers, one for each instrument, to create two rough shapes to measure the areas. The area of the shape will be measured using a Compensating Polar Planimeter.

    Time frame: From baseline to the end of treatment at 20 weeks

  3. Allodynia Area Mapping (paint brush)

    Paintbrush will be used to measure/map (cm²) out an area of neuropathic allodynia. The instrument will be used by pressing them against the neuropathic pain area and marking roughly 8 points with each. Then the points will be traced on two separate translucent papers, one for each instrument, to create two rough shapes to measure the areas. The area of the shapes will be measured using a Compensating Polar Planimeter.

    Time frame: From baseline to the end of treatment at 20 weeks

  4. QST Temperature Thresholds

    Thermal Sensory Analyzer (Medoc Advanced Medical Systems, Minneapolis) will be used to measure cool, warm, cold, and hot temperature (°C) thresholds. The participant will first be asked to press the button when the increasing hot temperature becomes uncomfortable. This will be done 3 times and averaged to establish a threshold for the next portion. The thermode will heat up to the threshold temperature and remain their for a period of time. The participant will then rate their pain experienced via MVAS scale (0-10) with a 0 describing no pain and a 10 describing the worst pain experienced. A lower pain score will represent a better outcome and a higher score will represent a worse outcome.

    Time frame: From baseline to end of treatment at 20 weeks

  5. von Frey Monofilament Threshold

    Different sized von Frey monofilament (e.g, 5.18) will be used to determine the participants physical pain sensation threshold to the von Frey monofilaments. The von Frey monofilaments will pressed against the neuropathic pain area one by one from smallest to largest until the participants expresses they can feel a sensation of physical pain in the neuropathic area caused by the von Frey monofilament.

    Time frame: From baseline to end of the treatment at 20 weeks

07

Study locations

1 of 1 sites recruiting
  • Veterans Medical Center - San Diego
    San Diego, California 92161, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Nov 2028, 43 months after the start.

Of 122 non-industry interventional studies with no phase under Peripheral Nervous System Diseases, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 43 months is above that.

Counting every sponsor, half of 132 studies reached it within 25 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Dec 24, 2025
StartActual
Apr 30, 2025
Primary completionEst.
Nov 2028
CompletionEst.
Mar 2029
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07301177
Lead sponsor
Veterans Medical Research Foundation
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Apr 30, 2025
Primary completion
Nov 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Dec 24, 2025

Study contacts

Brandon C Guarini, M.A.
Contact
brandon.guarini@va.gov
8586423146 ext. 3146
Caleb T Lopez, B.S.
Contact
caleb.lopez@va.gov
8585528585 ext. 2684
Albert Y Leung, M.D.
principal investigator · Veterans Medical Research Foundation (VMRF)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion